首頁(yè)
瀏覽量: 212
- 產(chǎn)品名稱(chēng)： Research Grade Belimumab ( 貝利木單抗 )
- 產(chǎn)品貨號(hào)： CSD00172
- 貨期： 現(xiàn)貨
- 價(jià)格與訂購(gòu)： 2480
- 數(shù)量：
庫(kù)存： 100
- 規(guī)格： 100μg
- 產(chǎn)品信息
- 如何訂購(gòu)
貨號(hào)（Catalog No.）
CSD00172
通用名INN
Belimumab
純度(Purity)
>95%
濃度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
內(nèi)毒素(Endotoxin level)
Please contact with the lab for this information.
產(chǎn)品描述(Description)
Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.
別名(Alternative names)
LymphoStat-B,hBlySmAb-1.1
靶點(diǎn);物種(Specificity target name;species)
TNFSF13B/CD257[Homo sapiens]
活性研究（體外/體內(nèi)研究）(Activity in vitro)
The ED50 is <20 ng/mL as measured by human RPMI 8226 cells, corresponding to a specific activity of >5.0 × 10^4 units/mg.
種類(lèi)(Species)
Homo sapiens
受體鑒定(Receptor identification)
IgG1-lambda
分子量(MV)
147000.0 Da
CAS
356547-88-1
存儲(chǔ)條件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .
地 址：
產(chǎn)品銷(xiāo)售：
E - mail ：
郵 編：
Amily
